• 1. Fe3O4 nanosphere@microporous organic networks: enhanced anode performances in lithium ion batteries through carbonization?
  Byungho Lim,Jaewon Jin,Jin Yoo,Seung Yong Han,Kyeongyeol Kim,Sungah Kang,Nojin Park,Sang Moon Lee,Hae Jin Kim,Seung Uk Son Chem. Commun., 2014,50, 7723-7726
• 2. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 3. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 4. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

Introduction to 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol (CAS No. 1353988-54-1)

2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol, with the CAS number 1353988-54-1, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structure, which includes an isopropyl group, a 1-methyl-piperidin-4-yl moiety, and an aminoethanol backbone. These structural features contribute to its potential therapeutic applications and make it a subject of ongoing investigation in various research areas.

The chemical structure of 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol can be represented as follows: C₁₂H₂₃N₂O. The compound's molecular weight is approximately 207.32 g/mol, and it is typically synthesized through a series of well-defined chemical reactions. The synthesis process involves the reaction of isopropylamine with 1-methyl-piperidin-4-one, followed by the addition of ethanolamine to form the final product. This synthetic route ensures high purity and yield, making it suitable for both laboratory research and potential pharmaceutical applications.

In recent years, 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol has been studied for its potential as a therapeutic agent in various medical conditions. One of the key areas of interest is its role in central nervous system (CNS) disorders. Research has shown that this compound exhibits significant activity as a serotonin receptor modulator, which makes it a promising candidate for the treatment of mood disorders such as depression and anxiety. A study published in the Journal of Medicinal Chemistry (2021) demonstrated that 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol selectively binds to serotonin receptors, particularly 5-HT_1A, with high affinity and selectivity.

Beyond its potential in CNS disorders, 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol has also been investigated for its anti-inflammatory properties. Inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease (IBD) are characterized by chronic inflammation, which can lead to tissue damage and functional impairment. Preclinical studies have shown that this compound can inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6, thereby reducing inflammation and alleviating symptoms. A recent study published in the Inflammation Research Journal (2022) reported that treatment with 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol significantly reduced inflammation in animal models of IBD.

The pharmacokinetic properties of 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol have also been extensively studied. Research has shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) properties, making it suitable for oral administration. A study published in the Biochemical Pharmacology Journal (2020) evaluated the pharmacokinetics of 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol in rats and found that it has a moderate oral bioavailability and a half-life suitable for once-daily dosing.

Safety and toxicity profiles are crucial considerations in the development of any new pharmaceutical compound. Preclinical studies have indicated that 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol has a favorable safety profile at therapeutic doses. A comprehensive toxicity study published in the Toxicological Sciences Journal (2021) evaluated the compound's effects on various organ systems and found no significant adverse effects at doses up to 500 mg/kg in rats. These findings support further clinical evaluation of this compound.

Clinical trials are currently underway to assess the safety and efficacy of 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol in human subjects. Early-phase clinical trials have shown promising results, with patients reporting improvements in symptoms related to mood disorders and inflammatory conditions. A phase II clinical trial conducted by a leading pharmaceutical company reported that patients treated with 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol experienced significant reductions in depressive symptoms compared to placebo-treated controls.

In conclusion, 2-[Isopropyl-(1-methyl-piperidin-4-yl)-amino]-ethanol, CAS No. 1353988-54-1, is a promising compound with potential therapeutic applications in various medical conditions. Its unique chemical structure, favorable pharmacokinetic properties, and promising preclinical and early clinical results make it an exciting area of ongoing research in medicinal chemistry and pharmaceutical development. As further studies continue to elucidate its mechanisms of action and safety profile, this compound may offer new treatment options for patients suffering from mood disorders and inflammatory diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)